TY - JOUR
T1 - Positive Urine Drug Screens and External Mortality in Teenagers Who Present for Medical Care
AU - Markota, Matej
AU - Croarkin, Paul E.
AU - Bobo, William V.
N1 - Funding Information:
This work was funded by the 2017 NIDA-AACAP Resident Training Award in Substance Use Disorders awarded to Dr Markota. Mentorship and guidance on this research project was received at the 2018 Research Colloquium for Junior Investigators, which was partially funded by the NIDA of the National Institutes of Health (NIH) under Award Number R13DA042568. This study was made possible using the resources of the Rochester Epidemiology Project, which is supported by the National Institute on Aging of the NIH under Award Number R01AG034676 (Co-PIs: Dr Walter A. Rocca and Dr Jennifer St. Sauver). Statistical support was received by Grant Number UL1 TR002377 from the National Center for Advancing Translational Sciences (NCATS). Research reported in this publication was also supported by the NIH under award R01 MH113700 by supporting research time for Dr Croarkin. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, National Institute on Drug Abuse, Rochester Epidemiology Project, or the American Academy of Child and Adolescent Ps chiatr
Funding Information:
(Co-PIs: Dr Walter A. Rocca and Dr Jennifer St. books/NBK423845/. St Sauver JL, Grossardt BR, Leibson CL, et al. Sauver). Statistical support was received by Grant Calabria B, Degenhardt L, Hall W, et al. Does Generalizability of epidemiological findings cannabis use increase the risk of death? Number UL1TR002377 from the National Center and public health decisions: an illustration systematicreviewofepidemiologicalevidencefor AdvancingTranslational Sciences (NCATS). from the Rochester Epidemiology Project. on adverse effects of cannabis use. Drug Research reported in this publication was also Mayo Clin Proc. 2012;87(2):151–160.PubMed CrossRef supported by the NIH under award R01 MH113700 Alcohol Rev. 2010;29(3):318–330.PubMed CrossRef Moeller KE, Lee KC, Kissack JC. Urine drug
Funding Information:
Submitted: October 22, 2020; accepted August American Academy of Child and Adolescent 2008;42(6):637–639.PubMed CrossRef 18, 2021. Psychiatry’s 65th Annual Meeting; October 22–27, 11. Gjersing L, Bretteville-Jensen AL. Patterns of Publishedonline:January11,2022. 2018; Seattle, Washington. substance use and mortality risk in a cohort Potential conflicts of interest:DrMarkota Additional information: Access to data presented of ‘hard-to-reach’ polysubstance users. has received a training research grant from the in this article is not publicly available, as data Addiction. 2018;113(4):729–739.PubMed CrossRef National Institute on Drug Abuse and American contain identifiable and protected information. Dillon FR, Turner CW, Robbins MS, et al. Academy of Child and Adolescent Psychiatry Supplementary material: Available at Concordance among biological, interview, (NIDA-AACAP). Dr Croarkin has received research PSYCHIATRIST.COM and self-report measures of drug use among grant support from Pfizer, the National Institute African American and Hispanic adolescents of Mental Health (NIMH), the Brain and Behavior referred for drug abuse treatment. Psychol Research Foundation, and Mayo Clinic. He has Addict Behav. 2005;19(4):404–413.PubMed CrossRef received equipment support from Neuronetics Redfield RR. CDC Director’s Media Statement Williams RJ, Nowatzki N. Validity of and MagVenture for investigator-initiated on US Life Expectancy. CDC website. https:// adolescent self-report of substance use. Subst studies. He received supplies and genotyping www.cdc.gov/media/releases/2018/s1129-US-Use Misuse. 2005;40(3):299–311.PubMed CrossRef services from Assurex Health for investigator-life-expectancy.html. Published 2018. Accessed Harrison L, Hughes A. Introduction–the initiated studies. He is a primary investigator for June 29, 2019. validity of self-reported drug use: improving a multicenter study funded by Neuronetics and Woolf SH, Schoomaker H. Life expectancy and the accuracy of survey estimates. NIDA Res a site primary investigator for a study funded mortality rates in the United States, 1959–2017. Monogr. 1997;167:1–16.PubMed by NeoSync. He has served as a paid consultant JAMA. 2019;322(20):1996–2016.PubMed CrossRef Cano M, Oh S, Salas-Wright CP, et al. Cocaine for Engrail Therapeutics, Myriad Neuroscience, Johnston LDM, O’Malley RA, Bachman PM, et use and overdose mortality in the United Procter & Gamble, and Sunovion. Dr Bobo has al. Monitoring the Future National Survey States: evidence from two national data received research support from NIMH, Agency for Results on Drug Use 1975–2018: Overview, Key sources, 2002-2018. Drug Alcohol Depend. Healthcare Research and Quality, and the Mayo Findings on Adolescent Drug Use. http://www. 2020;214:108148.PubMed CrossRef Foundation for Medical Education and Research. monitoringthefuture.org//pubs/monographs/ St Sauver JL, Grossardt BR, Yawn BP, et al. Use Funding/support:This work was funded by the mtf-overview2018.pdf. Published January 2019. of a medical records linkage system to 2017 NIDA-AACAP Resident Training Award in theRochester epidemiologyproject.Am J Accessed June 10, 2020.enumerate a dynamic population over time: Substance Use Disorders awarded to Dr Markota. Epidemiol. 2011;173(9):1059–1068.PubMed CrossRefEaton DK, Kann L, Kinchen S, et al; Centers for Mentorship and guidance on this research project Rocca WA, Yawn BP, St Sauver JL, et al. History Disease Control and Prevention (CDC). Youth was received at the 2018 Research Colloquium for MMWRSurveillSumm.2012;61(4):1–162.PubMedof the Rochester Epidemiology Project: half a risk behavior surveillance—United States, 2011. Junior Investigators, which was partially funded National Academies of Sciences Engineering century of medical records linkage in a US by the NIDA ofthe National Institutes of Health and Medicine (US). Committee on the Health population. Mayo Clin Proc. (NIH) under Award Number R13DA042568. This EffectsofMarijuana.The Health Effects of 2012;87(12):1202–1213.PubMedCrossRef CannabisandCannabinoids:TheCurrentStateofstudy was made possible using the resources 18. St Sauver JL, Grossardt BR, Finney Rutten LJ, EvidenceandRecommendationsforResearch. ofthe Rochester Epidemiology Project, which et al. Rochester Epidemiology Project Data Washington,DC:TheNationalAcademiesis supported by the National Institute on Aging Exploration Portal. Prev Chronic Dis. of the NIH under Award Number R01AG034676 Press; 2017. https://www.ncbi.nlm.nih.gov/ 2018;15:E42.PubMed CrossRef
Publisher Copyright:
© Copyright 2022 Physicians Postgraduate Press, Inc.
PY - 2022/1
Y1 - 2022/1
N2 - Objective: To examine whether a positive urine drug of abuse screen in youth who receive medical care is associated with subsequent risk of external mortality (eg, overdose, suicide, homicide, accident). Methods: This was a population-based retrospective cohort study of all Olmsted County (Minnesota) residents who were 13–18 years of age at the time of urine drug screen (UDS) testing (January 1, 1999, to November 28, 2012). Cox regression models were used to examine the relationships between having a positive UDS and external mortality, adjusted for sex, race, age, alcohol exposure, psychiatric diagnoses as defined by the International Classification of Diseases (ICD-9/ICD-10), and medical setting of UDS testing. Separate analyses were done for (1) overall UDS results, (2) tetrahydrocannabinol (THC), and (3) cocaine. Results: Of the 2,772 teenagers included in this study (47.2% male), a total of 26 died of external causes during a median follow-up period of 11.8 years. Testing positive for any illicit substance was not associated with significantly increased risk of external mortality (hazard ratio [HR] = 1.9; 95% CI, 0.9–4.2). Testing positive for cocaine was associated with significantly increased risk of external mortality (HR = 7.0; 95% CI, 1.9–25.0). Testing positive for THC was associated with a marginally significantly increased risk of external mortality (HR = 2.1; 95% CI, 1.0–4.7); however, when cocaine was added as a covariate in the analysis, the relationship between THC-positive UDS and mortality was still elevated but was no longer statistically significant (HR = 1.8; 95% CI, 0.8–4.1). Conclusions: History of cocaine-positive UDS may help identify a population of young people who are at high risk of premature death.
AB - Objective: To examine whether a positive urine drug of abuse screen in youth who receive medical care is associated with subsequent risk of external mortality (eg, overdose, suicide, homicide, accident). Methods: This was a population-based retrospective cohort study of all Olmsted County (Minnesota) residents who were 13–18 years of age at the time of urine drug screen (UDS) testing (January 1, 1999, to November 28, 2012). Cox regression models were used to examine the relationships between having a positive UDS and external mortality, adjusted for sex, race, age, alcohol exposure, psychiatric diagnoses as defined by the International Classification of Diseases (ICD-9/ICD-10), and medical setting of UDS testing. Separate analyses were done for (1) overall UDS results, (2) tetrahydrocannabinol (THC), and (3) cocaine. Results: Of the 2,772 teenagers included in this study (47.2% male), a total of 26 died of external causes during a median follow-up period of 11.8 years. Testing positive for any illicit substance was not associated with significantly increased risk of external mortality (hazard ratio [HR] = 1.9; 95% CI, 0.9–4.2). Testing positive for cocaine was associated with significantly increased risk of external mortality (HR = 7.0; 95% CI, 1.9–25.0). Testing positive for THC was associated with a marginally significantly increased risk of external mortality (HR = 2.1; 95% CI, 1.0–4.7); however, when cocaine was added as a covariate in the analysis, the relationship between THC-positive UDS and mortality was still elevated but was no longer statistically significant (HR = 1.8; 95% CI, 0.8–4.1). Conclusions: History of cocaine-positive UDS may help identify a population of young people who are at high risk of premature death.
UR - http://www.scopus.com/inward/record.url?scp=85136575173&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85136575173&partnerID=8YFLogxK
U2 - 10.4088/JCP.20m13729
DO - 10.4088/JCP.20m13729
M3 - Article
C2 - 35015935
AN - SCOPUS:85136575173
SN - 0160-6689
VL - 83
JO - Journal of Clinical Psychiatry
JF - Journal of Clinical Psychiatry
IS - 1
M1 - 20m13729
ER -